WO1995025118A3 - Inhibitors of sh2 domain interactions - Google Patents

Inhibitors of sh2 domain interactions Download PDF

Info

Publication number
WO1995025118A3
WO1995025118A3 PCT/US1995/003225 US9503225W WO9525118A3 WO 1995025118 A3 WO1995025118 A3 WO 1995025118A3 US 9503225 W US9503225 W US 9503225W WO 9525118 A3 WO9525118 A3 WO 9525118A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
domain interactions
domain
phosphotyrosine
inhibiting
Prior art date
Application number
PCT/US1995/003225
Other languages
French (fr)
Other versions
WO1995025118A2 (en
Inventor
William W Bachovchin
Original Assignee
Trustees Of Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Tufts University filed Critical Trustees Of Tufts University
Publication of WO1995025118A2 publication Critical patent/WO1995025118A2/en
Publication of WO1995025118A3 publication Critical patent/WO1995025118A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention makes available novel compounds useful for inhibiting an interaction between a protein containing an SH2 domain and a phosphotyrosine-containing polypeptide represented by general formula (II).
PCT/US1995/003225 1994-03-15 1995-03-15 Inhibitors of sh2 domain interactions WO1995025118A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/214,643 1994-03-15
US08/214,643 US5580979A (en) 1994-03-15 1994-03-15 Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions

Publications (2)

Publication Number Publication Date
WO1995025118A2 WO1995025118A2 (en) 1995-09-21
WO1995025118A3 true WO1995025118A3 (en) 1995-11-16

Family

ID=22799886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003225 WO1995025118A2 (en) 1994-03-15 1995-03-15 Inhibitors of sh2 domain interactions

Country Status (2)

Country Link
US (2) US5580979A (en)
WO (1) WO1995025118A2 (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116365A1 (en) * 2002-12-10 2004-06-17 Isis Pharmaceuticals Inc. Modulation of Lck expression
US5776716A (en) * 1994-02-01 1998-07-07 Terrapin Technologies, Inc. Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof
US6770446B1 (en) * 1994-06-14 2004-08-03 Wyeth Cell systems having specific interaction of peptide binding pairs
HUP9802078A3 (en) * 1995-02-10 1999-04-28 Smithkline Beecham Corp Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
EP0728482A3 (en) * 1995-02-10 1999-10-20 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis
WO1996027797A2 (en) * 1995-03-08 1996-09-12 Hsc Research And Development Limited Partnership Zap 70 inhibitors and methods for treatment of zap 70 signal transduction disorders
WO1997002024A1 (en) * 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
US5776696A (en) * 1995-09-15 1998-07-07 Merck & Co., Inc. High throughput assay using fusion proteins
EP0871648A1 (en) * 1995-09-15 1998-10-21 Merck & Co., Inc. A high throughput assay using fusion proteins
US5783398A (en) * 1995-09-15 1998-07-21 Merck & Co., Inc. High throughput assay using fusion proteins
CA2207973A1 (en) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation of integrin-mediated signal transduction
AU7521196A (en) * 1995-10-27 1997-05-15 Asahi Chemical Industry Co. Ltd. Peptide inhibitors of a phosphotyrosine-binding domain containing protein
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
ATE220110T1 (en) 1996-04-11 2002-07-15 Mitotix Inc ASSAY AND REAGANTS FOR IDENTIFYING FUNGICIDAL ACTIVE INGREDIENTS AND THEIR USES
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
CA2253776A1 (en) * 1996-05-07 1997-11-13 Boehringer Ingelheim Pharmaceuticals, Inc. Phosphotyrosine mimics and methods for identifying and using same
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
EP0939815A1 (en) * 1996-11-18 1999-09-08 Cor Therapeutics, Inc. IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION
US6194557B1 (en) 1996-11-18 2001-02-27 Cor Therapeutics, Inc. Nucleic acid molecules encoding Bap-1 proteins
WO1998024805A1 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
JP4094066B2 (en) * 1996-12-06 2008-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitor of interleukin-1β converting enzyme
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US6683075B1 (en) 1996-12-23 2004-01-27 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US20030096760A1 (en) * 1997-03-10 2003-05-22 Smithklinebeecham Corporation Method of antagonizing the human SRC SH2 domain
JP2001514662A (en) * 1997-03-10 2001-09-11 スミスクライン・ビーチャム・コーポレイション Method of antagonizing human src SH2 domain
WO1998046626A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
EP0975625A1 (en) 1997-04-14 2000-02-02 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6333321B1 (en) * 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6312941B1 (en) 1997-11-26 2001-11-06 The Regents Of The University Of Michigan Compositions and methods for identifying signaling pathway agonists and antagonists
EP1037981A1 (en) * 1997-12-09 2000-09-27 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
US6156784A (en) * 1997-12-18 2000-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
EP1045836B1 (en) * 1997-12-18 2008-03-05 Boehringer Ingelheim Pharmaceuticals Inc. Pyridones as src family sh2 domain inhibitors
CA2307221A1 (en) * 1997-12-22 1999-07-01 Elan Pharmaceuticals, Inc. Polycyclic .alpha.-amino-e-caprolactams and related compounds
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
US6528505B1 (en) 1998-06-22 2003-03-04 Elan Pharmaceuticals, Inc. Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6569851B1 (en) 1998-06-22 2003-05-27 Elan Pharmaceutials, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6774125B2 (en) 1998-06-22 2004-08-10 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2782997A1 (en) * 1998-09-08 2000-03-10 Hoechst Marion Roussel Inc NOVEL BENZODIAZEPINONE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF, MEDICAMENT APPLICATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
US6355786B1 (en) * 1998-10-30 2002-03-12 Vanderbilt University Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
WO2000056760A1 (en) * 1999-03-23 2000-09-28 The United States Of America, Represented By Secretary, Department Of Health And Human Services Phenylalanine derivatives
FR2796381A1 (en) * 1999-07-12 2001-01-19 Hoechst Marion Roussel Inc Thiazepin and caprolactam bicyclic derivatives, useful in the treatment of e.g. osteoporosis and other bone disorders, infections, allergies or cancers
DE60034959T2 (en) 1999-10-22 2008-01-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services INHIBITIONS OF CELL MUTILITY AND ANGIOGENESIS WITH GRB2 SH2 DOMAIN INHIBITORS
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
EP1383792A2 (en) * 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Sh2 domain binding inhibitors
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
JP4771661B2 (en) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Post-proline cleavage enzyme pseudopeptide inhibitor
WO2003045228A2 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
EP1499336A4 (en) * 2002-04-30 2005-06-01 Tufts College Protease inhibitors
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
CN1894234A (en) 2003-03-25 2007-01-10 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (en) 2003-08-13 2006-08-25 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors.
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
BRPI0507972A (en) * 2004-02-23 2007-07-24 Tufts College compound, pharmaceutical composition, use of a compound, method for inhibiting the proteolytic activity of a postproline cleavage enzyme and packaged pharmaceutical composition
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (en) 2004-03-15 2020-08-25 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
WO2005114197A2 (en) 2004-04-15 2005-12-01 Albert Einstein College Of Medicine Of Yeshiva University Activity-based probes for protein tyrosine phosphatases
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
WO2006125304A1 (en) * 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
EP1986634A2 (en) * 2005-10-12 2008-11-05 Trojanon GmbH & Co. KG Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2663279C (en) * 2006-09-13 2016-05-17 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8466096B2 (en) * 2007-04-26 2013-06-18 Afton Chemical Corporation 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions
AR081930A1 (en) 2010-06-16 2012-10-31 Ardea Biosciences Inc THIOACETATE COMPOUNDS
EP2753334B1 (en) 2011-08-30 2022-10-19 Trustees Of Tufts College Fap-activated proteasome inhibitors for treating solid tumors
CN108721622B (en) * 2017-04-14 2022-10-25 中国科学院上海高等研究院 Reagent for inhibiting hepatic fibrosis and application thereof
CN109627313B (en) * 2017-10-09 2020-07-10 华中科技大学 Mutant IRS-1 PTB structural domain protein, coding sequence and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3204403A1 (en) * 1982-02-09 1983-08-11 Dr. Karl Thomae Gmbh, 7950 Biberach NEW PYRIDOBENZODIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US4755508A (en) * 1984-06-26 1988-07-05 Merck & Co., Inc. Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
US4594191A (en) * 1985-04-22 1986-06-10 Merck & Co., Inc. Process for preparing a benzodiazepinedione derivative
US4628084A (en) * 1986-01-02 1986-12-09 Merck & Co., Inc. Process for 3-acylamino benzodiazepines
DE3610848A1 (en) * 1986-04-01 1987-10-15 Boehringer Ingelheim Kg NEW 1,4-DIAZEPINE
US4650797A (en) * 1986-07-18 1987-03-17 E. R. Squibb & Sons, Inc. Substituted 1,5-benzodiazepine compounds
US4898861A (en) * 1987-03-26 1990-02-06 Hoffmann-La Roche Inc. Method for inhibiting the proliferation of tumor cells
US4957915A (en) * 1989-02-27 1990-09-18 Biomeasure, Inc. Benzodiazepine analogs
US5175159A (en) * 1989-10-05 1992-12-29 Merck & Co., Inc. 3-substituted-1,4-benzodiazepines as oxytocin antagonists
EP0559793A1 (en) * 1990-11-30 1993-09-15 Smithkline Beecham Corporation Hiv protease inhibitors
CA2056809A1 (en) * 1990-12-07 1992-06-08 Mark G. Bock Benzodiazepine analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A.F. Spatola ' Peptide Backbone Modifications: A Structure-Activity *
R.M. Freidinger 'Design and comparison of *
SAMANEN, J. ET AL: "Effects of D-amino acid substitution on antagonist activities of angiotensin II analogs", J. MED. CHEM. (1988), 31(3), 510-16 CODEN: JMCMAR;ISSN: 0022-2623 *
SAMANEN, JAMES ET AL: "The role of position four in angiotensin II antagonism: a structure-activity study", J. MED. CHEM. (1989), 32(6), 1366-70 CODEN: JMCMAR;ISSN: 0022-2623 *
W.J. FANTL ET AL.: "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways", CELL, vol. 69, 1 May 1992 (1992-05-01), NA US, pages 413 - 423 *
Z. SONGYANG ET AL.: "SH2 Domains Recognize Specific Phosphopeptide Sequences", CELL, vol. 72, 12 March 1992 (1992-03-12), NA US, pages 767 - 778 *

Also Published As

Publication number Publication date
WO1995025118A2 (en) 1995-09-21
US5580979A (en) 1996-12-03
US5776902A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
WO1995025118A3 (en) Inhibitors of sh2 domain interactions
AU688952B2 (en) Thrombin inhibitors
HK1004638A1 (en) Multicatalytic protease inhibitors.
EP0820287A4 (en) Thrombin inhibitors
AU1980997A (en) Synthetic Multimerizing Agents
AU2191492A (en) Novel phospholipase a2 inhibitors
AU2464601A (en) Tricyclic protein kinase inhibitors
AU658296B2 (en) 7 beta-substituted-4-aza-5 alpha-cholestan-3-ones as 5 alpha-reductase inhibitors
AU7392696A (en) Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
AU7317391A (en) Inhibitor of denatured ldl formation
WO2000034437A3 (en) Inhibitors of prenyl-protein transferase
NO972346L (en) Aminoguanidine carboxylates for the treatment of non-insulin dependent diabetes millitus
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
AU4789297A (en) Method for the detection of compounds that modulate the effects of the obese (ob) protein
AU2545697A (en) Novel uses of phospholipase c inhibitors
AU7257994A (en) Novel protein inhibitors of serine proteinases (e.g. furin) derived from turkey ovomucoid third domain
AU4676393A (en) Compounds for inhibition of proteolysis
AU7521196A (en) Peptide inhibitors of a phosphotyrosine-binding domain containing protein
AU667777B2 (en) Alicyclic phospholipase A2 inhibitors
AU6802794A (en) Inhibitors of nef-cd4 binding
AU662224B2 (en) New 7beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
IE892191L (en) 3-KETO HMG-CoA REDUCTASE INHIBITORS
MX9701881A (en) Method for detection of malfolded protein.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA